Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
about
The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in ChinaInfiltrative CardiomyopathiesRecent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapiesAmyloid diseases of the heart: current and future therapiesRationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisImproved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyUtility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosiImplantable cardioverter defibrillators in patients with cardiac amyloidosis.A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow upTroponin: the biomarker of choice for the detection of cardiac injuryRecent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis.T1 mapping and survival in systemic light-chain amyloidosis.Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trialAmyloidosis: pathogenesis and new therapeutic options.Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operativAbnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death.High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.Current perspectives on cardiac amyloidosis.Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo stagingImpact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).Updates in cardiac amyloidosis: a review.The amyloidoses: clinical features, diagnosis and treatment.Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management.Al amyloidosisIncomplete ileus and hemafecia as the presenting features of multi-organ involved primary systemic AL amyloidosis: a rare case report.Cardiac amyloidosis presenting as recurrent acute coronary syndrome with unobstructed coronary arteries: Case report.Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?A prospective study of nutritional status in immunoglobulin light chain amyloidosis.Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
P2860
Q26740439-D8832A8A-C593-4C50-86A7-8DD0FEFF8D22Q26798533-67838008-9D99-4C61-9FA5-4CEC62A52A25Q27002436-D6763112-0BAF-4309-B402-C01FB570A54AQ27023836-4C2D453F-5EFB-4E6A-A648-81F0997027E3Q28069975-B66E5AE2-CA97-4E21-BA61-536D7CB43E2AQ30278687-0B9D49AF-35E1-425F-AD04-70981996ECBBQ30469018-BE01244F-4A97-4902-94E5-0D3AA382FC87Q33162514-C3A62155-E5B1-49E7-9C92-30CD1E5C1AD6Q33165133-15239A85-9797-42B4-8B61-9D3811FF8DCAQ33417805-F38C1B75-F062-4FE4-9ACA-D2100902E792Q33427726-C25C0FBA-59DD-4A6B-A03A-628F6E37F93CQ33439299-74E72EFF-DD08-4340-8D4B-5B1CE604D77EQ34117708-CE531067-D745-4BD2-A86B-5748D5D38068Q34450910-72C14427-C77B-405F-A36B-359C138BF11DQ34768284-4B3EA5B3-983B-467A-AD89-3F0FA375D43AQ34994098-7FD0992F-06F6-4543-B009-6E30B2178689Q35081363-54198406-BC65-4C7E-8BE6-0DD55B10D73DQ35111771-74161DA0-B2D1-461B-BDA0-17465EF068DBQ35571048-90CCBD4D-23EA-482A-B936-46388CB98CEEQ35579434-1028657D-8B11-439E-A7DF-67C39EF59FA3Q35750326-4C8EA65E-4041-46B5-B506-9860677C73F5Q35964900-215CD4DF-0A48-4502-9818-CC13BB412081Q36015183-A96AC98E-4376-4EE5-9A28-CD359BDEB0CAQ36036322-B064E754-21AB-4C78-A84A-764B5DA40471Q36163205-6586BE23-9D35-4BBC-9563-091E58F151D0Q36165179-89ACE47B-C1A6-494E-AC01-63B094FD8429Q36288753-8A5A4899-C0DD-41D3-8739-F8C4564FE224Q36338381-BC21107D-D564-4EC2-9D66-9AC31295C8BEQ36366356-C975D9B4-E589-49DD-96E0-B9DA95D75D95Q36366997-A7016D38-9FFA-44DE-809B-A04869021172Q36367005-86033E34-53EB-4A0C-9268-35D918D48B00Q36392233-410CE1F7-C77A-4174-8A5E-03F5B884A4BEQ36393248-435CFBAA-AD8F-4A57-98E5-C590FAFB6BBCQ36426658-7D160479-7946-4B43-ADD4-3AC93202BCCCQ36484561-0061475B-A685-4B40-A2A1-33E6378BBDF7Q36498408-2A3C03A9-29C5-4F64-A389-E8639908DBADQ36779759-4ECAA7D5-86BB-43A1-9919-30F6A64DFB37Q36824706-7816A1D7-3042-4794-8045-F4EABA128DB6Q36892637-A5567972-C80B-403A-B9FF-A5C54E28D3EBQ36910372-2C14A535-7886-4056-B59A-5EE82F550E41
P2860
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Serum cardiac troponins and N- ...... primary systemic amyloidosis.
@ast
Serum cardiac troponins and N- ...... primary systemic amyloidosis.
@en
type
label
Serum cardiac troponins and N- ...... primary systemic amyloidosis.
@ast
Serum cardiac troponins and N- ...... primary systemic amyloidosis.
@en
prefLabel
Serum cardiac troponins and N- ...... primary systemic amyloidosis.
@ast
Serum cardiac troponins and N- ...... primary systemic amyloidosis.
@en
P2093
P50
P356
P1476
Serum cardiac troponins and N- ...... primary systemic amyloidosis.
@en
P2093
Allan S Jaffe
Christopher G A McGregor
John A Lust
Mary F Burritt
Philip R Greipp
Rafael Fonseca
Terry M Therneau
Thomas E Witzig
P304
P356
10.1200/JCO.2004.03.029
P407
P577
2004-09-01T00:00:00Z